Skip to main content

Advertisement

SpringerLink
Log in

Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication Use

  • Original Article
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

BACKGROUND

Increased use of generic medications conserves insurer and patient financial resources and may increase patient adherence.

OBJECTIVE

The objective of the study is to evaluate whether physician, patient, pharmacy benefit design, or pharmacy characteristics influence the likelihood that patients will use generic drugs

DESIGN, SETTING, AND PARTICIPANTS

Observational analysis of 2001–2003 pharmacy claims from a large health plan in the Western United States. We evaluated claims for 5,399 patients who filled a new prescription in at least 1 of 5 classes of chronic medications with generic alternatives. We identified patients initiated on generic drugs and those started on branded medications who switched to generic drugs in the subsequent year. We used generalized estimating equations to perform separate analyses assessing the relationship between independent variables and the probability that patients were initiated on or switched to generic drugs.

RESULTS

Of the 5,399 new prescriptions filled, 1,262 (23.4%) were generics. Of those initiated on branded medications, 606 (14.9%) switched to a generic drug in the same class in the subsequent year. After regression adjustment, patients residing in high-income zip codes were more likely to initiate treatment with a generic than patients in low-income regions (RR = 1.29; 95% C.I. 1.04–1.60); medical subspecialists (RR = 0.82; 0.69–0.95) and obstetrician/gynecologists (RR = 0.81; 0.69–0.98) were less likely than generalist physicians to initiate generics. Pharmacy benefit design and pharmacy type were not associated with initiation of generic medications. However, patients were over 2.5 times more likely to switch from branded to generic medications if they were enrolled in 3-tier pharmacy plans (95% C.I. 1.12–6.09), and patients who used mail-order pharmacies were 60% more likely to switch to a generic (95% C.I. 1.18–2.30) after initiating treatment with a branded drug.

CONCLUSIONS

Physician and patient factors have an important influence on generic drug initiation, with the patients who live in the poorest zip codes paradoxically receiving generic drugs least often. While tiered pharmacy benefit designs and mail-order pharmacies helped steer patients towards generic medications once the first prescription has been filled, they had little effect on initial prescriptions. Providing patients and physicians with information about generic alternatives may reduce costs and lead to more equitable care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. IMS Health. Available at: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_77180090,00.html . Accessed February 5, 2007.

  2. Heffler S, Levit K, Smith et al. Health spending growth up in 1999; faster growth expected in the future. Health Aff. 2001;20(2):193–203.

    Article  CAS  Google Scholar 

  3. Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM. Projecting future drug expenditures—2004. Am J Health Syst Pharm. 2004;61(2):145–58.

    PubMed  Google Scholar 

  4. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13(4):207–14.

    Article  PubMed  Google Scholar 

  5. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850–6.

    Article  PubMed  CAS  Google Scholar 

  6. Kohl H, Shrank WH. Increasing generic drug use in Medicare Part D: The role of government. J Am Geriatr Soc. 2007;55(7):1106–9

    Article  PubMed  Google Scholar 

  7. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med. 2005;142(11):891–7.

    PubMed  Google Scholar 

  8. Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2004 summary of findings. (Accessed October 12, 2004, at http://www.kff.org/insurance/7148/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=46206 )

  9. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med. 2006;166:332–7.

    Article  PubMed  Google Scholar 

  10. Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care. 2007;45(2):109–15 (Feb).

    Article  PubMed  Google Scholar 

  11. Federman AD, Halm EA, Zhu C, Hochman T, Siu AL. Association of income and prescription drug coverage with generic medication use among older adults with hypertension. Am J Manag Care. 2006;12(10):611–8 (Oct).

    PubMed  Google Scholar 

  12. Shrank WH, Fox SA, Kirk A, et al. The Effect of Pharmacy Benefit Design on Patient-Physician Communication about Costs. J Gen Intern Med. 2006;21(4):334-9.

    Article  PubMed  Google Scholar 

  13. Shrank WH, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care. 2005;11(1):16–22.

    PubMed  Google Scholar 

  14. Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients’ out-of-pocket prescription costs. Arch Intern Med. 2005;165(6):633–6.

    Article  PubMed  Google Scholar 

  15. Oregon Health Sciences University. Drug Evaluation Review Project. Accessed 12/19/05 at: http://www.ohsu.edu/drugeffectiveness/reports/index.htm .

  16. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–48, Jun.

    Article  PubMed  CAS  Google Scholar 

  17. Soobader M, LeClere FB, Hadden W, Maury B. Using aggregate geographic data to proxy individual socioeconomic status: does size matter? Am J Public Health. 2001;91:632–6.

    Article  PubMed  CAS  Google Scholar 

  18. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol. 1998;148(5):475–86.

    PubMed  CAS  Google Scholar 

  19. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(9):854–64 (Nov 1).

  20. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren JL. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(8 Suppl):IV-82–95.

    Google Scholar 

  21. Shea JA, Kletke PR, Wozniak GD, Polsky D, Escarce JJ. Self-reported physician specialties and the primary care content of medical practice: a study of the AMA physician masterfile. American Medical Association. Med Care. 1999;37(4):333–8.

    Article  PubMed  CAS  Google Scholar 

  22. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41(3):398–406.

    Article  PubMed  Google Scholar 

  23. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 349(23):2224–32.

  24. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346(11):822–9.

    Article  PubMed  Google Scholar 

  25. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;(10):621–8.

  26. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–50.

    Article  PubMed  CAS  Google Scholar 

  27. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293–304.

    Article  PubMed  CAS  Google Scholar 

  28. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood). 2004;Suppl Web Exclusives:W4-455–68.

  29. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730–40.

    PubMed  Google Scholar 

  30. Shrank WH. The effect of incentive-based formularies on drug utilization and spending. N Engl J Med. 2004;350(10):1057.

    Article  PubMed  CAS  Google Scholar 

  31. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf. 2005;14(11):789–93.

    Article  PubMed  CAS  Google Scholar 

  32. IMS Health. 2004 year end U.S. prescription and sales information and commentary. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_69890098,00.html. Accessed 5/14/07.

  33. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med. 2005;118(8):881–4.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None disclosed.

Author information

Authors and Affiliations

  1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA, 02120, USA

    William H. Shrank MD, MSHS, Margaret Stedman MPH, M. Alan Brookhart PhD, Michael A. Fischer MD & Jerry Avorn MD

  2. VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

    Steven M. Asch MD, MPH

  3. RAND Health, Los Angeles, CA, USA

    Steven M. Asch MD, MPH

  4. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Susan L. Ettner PhD & Steven M. Asch MD, MPH

  5. Anthem Blue Cross Blue Shield, North Haven, CT, USA

    Dee DeLapp RPh & June Dirstine

  6. Anthem Prescription Management, North Haven, CT, USA

    Dee DeLapp RPh & June Dirstine

Authors
  1. William H. Shrank MD, MSHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret Stedman MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan L. Ettner PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dee DeLapp RPh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. June Dirstine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Alan Brookhart PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael A. Fischer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jerry Avorn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Steven M. Asch MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William H. Shrank MD, MSHS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shrank, W.H., Stedman, M., Ettner, S.L. et al. Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication Use. J GEN INTERN MED 22, 1298–1304 (2007). https://doi.org/10.1007/s11606-007-0284-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-007-0284-3

Key words

Search

Navigation